🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Dieckol, a phlorotannin from Ecklonia cava, alleviates stress hormone-induced depressive-like behaviors through glucocorticoid receptor antagonism.

PMID: 41650520 · DOI: 10.1016/j.phymed.2026.157906 · Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026 · Inhye Park, Jung-Eun Lee, Minji Kim, Minseok Yoon, Min Jung Kim, Min-Sun Kim, Suengmok Cho, Min Young Um
📄 Abstract

Depression imposes significant social, economic, and health burdens worldwide. Although phlorotannin-rich extract from Ecklonia cava (PS) and its active compound dieckol (DK) exhibit various biological activities, their antidepressant- and anxiolytic-like effects and underlying mechanisms remain unclear. This study investigated the antidepressant- and anxiolytic-like potential of PS and DK in a corticosterone (CORT)-induced mouse model of depression and anxiety, focusing on glucocorticoid receptor (GR) signaling. CORT-treated mice were orally administered PS or DK, and behavioral tests were performed to assess depressive- and anxiety-like behaviors. PS composition was analyzed using LC-MS/MS. Molecular docking predicted the binding of PS components to GR. GR nuclear translocation, target gene expression, and downstream signaling were examined using behavioral, molecular, and computational approaches. PS alleviated CORT-induced depressive- and anxiety-like behaviors, accompanied by reduced GR nuclear translocation, suppression of Mkp-1, and restoration of ERK-CREB-BDNF signaling. Molecular docking analysis predicted strong binding of DK to the GR ligand-binding domain. Consistently, DK reduced GR nuclear translocation and GRE binding, downregulated GR target genes (Mkp-1, Sgk-1, Fkbp5, and Bdnf), and restored ERK-CREB-BDNF signaling. In vivo, DK also improved CORT-induced behavioral deficits and normalized HPA axis activity and neurotransmitter levels. Collectively, our results suggest that DK, a major bioactive phlorotannin from E. cava, exerts antidepressant- and anxiolytic-like effects in association with modulation antagonism of GR signaling, highlighting its therapeutic potential as a natural GR-modulating agent for stress-related mood disorders.

Confidence: 0.37 · 19 полей извлечено
Идентификация (6 полей)
Target
Glucocorticoid receptor
0.95
Alt. target
GR
0.95
Protein family
Nuclear receptor family
0.90
Functional class
Ligand-activated transcription factor
0.90
Subcellular loc.
Cytoplasm and nucleus
0.85
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
glucocorticoid receptor antagonism
0.95
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
modulates glucocorticoid receptor signaling, normalizes HPA axis activity
0.90
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
corticosterone
0.85
Upstream (physiol)
stress
0.80
Downstream (biochem)
Mkp-1, Sgk-1, Fkbp5, Bdnf, ERK, CREB
0.90
Downstream (physiol)
HPA axis activity, neurotransmitter levels
0.85
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
Corticosterone (CORT)-induced mouse model of depression and anxiety; behavioral tests; oral administration of PS or DK; assessment of depressive- and anxiety-like behaviors; GR nuclear translocation; target gene expression; downstream signaling; HPA axis activity; neurotransmitter levels
0.95
In silico
Molecular docking predicted binding of PS components to GR; molecular docking analysis predicted strong binding of DK to the GR ligand-binding domain
0.95
Genetic association
0.00
Ex vivo
0.00
Animal model
Corticosterone (CORT)-induced mouse model of depression and anxiety
0.95
Diet/model
Corticosterone (CORT)-induced mouse model
0.95
Клиника (11 полей)
Drug
Dieckol
0.95
Indication
Stress-related mood disorders, depression, anxiety
0.90
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
Preclinical
0.85
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
False
0.90